Easing the Burden of Biotherapeutic Characterization Method Transfers
Mihir Thakar, MSc
Attention to consistency is pivotal to transferring and optimizing characterization methods
biosimilars
FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases
U.S. Food and Drug Administration
Wezlana has similar safety and efficacy as its reference product and is a cost-effective alternative for chronic inflammation
FDA Approves First Biosimilar to Treat Multiple Sclerosis
U.S. Food and Drug Administration
Tyruko® has been shown to safely mitigate and manage inflammation in autoimmune conditions like Crohn’s disease